Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc Wins U.S. Approval For New Flu Vaccine-Reuters


Monday, 17 Dec 2012 10:58am EST 

Reuters reported that U.S. health regulators have approved a new four strain seasonal influenza vaccine made by Glaxosmithkline Plc. The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children age 3 and older and adults against flu virus subtypes A and B contained in the vaccine. Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain. 

Company Quote

47.7
-0.11 -0.23%
21 Aug 2014